348 related articles for article (PubMed ID: 10746637)
1. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat.
Ke HZ; Qi H; Crawford DT; Chidsey-Frink KL; Simmons HA; Thompson DD
Endocrinology; 2000 Apr; 141(4):1338-44. PubMed ID: 10746637
[TBL] [Abstract][Full Text] [Related]
2. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats.
Ke HZ; Qi H; Chidsey-Frink KL; Crawford DT; Thompson DD
J Bone Miner Res; 2001 Apr; 16(4):765-73. PubMed ID: 11316005
[TBL] [Abstract][Full Text] [Related]
3. A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.
Armamento-Villareal R; Sheikh S; Nawaz A; Napoli N; Mueller C; Halstead LR; Brodt MD; Silva MJ; Galbiati E; Caruso PL; Civelli M; Civitelli R
J Bone Miner Res; 2005 Dec; 20(12):2178-88. PubMed ID: 16294271
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin E2 administration prevents bone loss induced by orchidectomy in rats.
Li M; Jee WS; Ke HZ; Tang LY; Ma YF; Liang XG; Setterberg RB
J Bone Miner Res; 1995 Jan; 10(1):66-73. PubMed ID: 7747632
[TBL] [Abstract][Full Text] [Related]
5. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.
Ke HZ; Simmons HA; Pirie CM; Crawford DT; Thompson DD
Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465
[TBL] [Abstract][Full Text] [Related]
6. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.
Ke HZ; Paralkar VM; Grasser WA; Crawford DT; Qi H; Simmons HA; Pirie CM; Chidsey-Frink KL; Owen TA; Smock SL; Chen HK; Jee WS; Cameron KO; Rosati RL; Brown TA; Dasilva-Jardine P; Thompson DD
Endocrinology; 1998 Apr; 139(4):2068-76. PubMed ID: 9528995
[TBL] [Abstract][Full Text] [Related]
7. Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
Ke HZ; Chen HK; Qi H; Pirie CM; Simmons HA; Ma YF; Jee WS; Thompson DD
Bone; 1995 Nov; 17(5):491-6. PubMed ID: 8579962
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats.
Ke HZ; Foley GL; Simmons HA; Shen V; Thompson DD
Endocrinology; 2004 Apr; 145(4):1996-2005. PubMed ID: 14726439
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
Ke HZ; Chen HK; Simmons HA; Qi H; Crawford DT; Pirie CM; Chidsey-Frink KL; Ma YF; Jee WS; Thompson DD
Bone; 1997 Jan; 20(1):31-9. PubMed ID: 8988345
[TBL] [Abstract][Full Text] [Related]
10. Effects of lasofoxifene on bone in surgically postmenopausal cynomolgus monkeys.
Lees C; Shen V; Brommage R
Menopause; 2007; 14(1):97-105. PubMed ID: 17075430
[TBL] [Abstract][Full Text] [Related]
11. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
12. Effects of tower climbing exercise on bone mass, strength, and turnover in orchidectomized growing rats.
Notomi T; Okazaki Y; Okimoto N; Tanaka Y; Nakamura T; Suzuki M
J Appl Physiol (1985); 2002 Sep; 93(3):1152-8. PubMed ID: 12183513
[TBL] [Abstract][Full Text] [Related]
13. Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats.
Nuttall ME; Bradbeer JN; Stroup GB; Nadeau DP; Hoffman SJ; Zhao H; Rehm S; Gowen M
Endocrinology; 1998 Dec; 139(12):5224-34. PubMed ID: 9832463
[TBL] [Abstract][Full Text] [Related]
14. Droloxifene does not blunt bone anabolic effects of prostaglandin E2, but maintains prostaglandin E2-restored bone in aged, ovariectomized rats.
Ke HZ; Crawford DT; Qi H; Pirie CM; Simmons HA; Chidsey-Frink KL; Chen HK; Jee WS; Thompson DD
Bone; 1999 Jan; 24(1):41-7. PubMed ID: 9916783
[TBL] [Abstract][Full Text] [Related]
15. Effects of the selective estrogen receptor modulator ospemifene on bone in rats.
Kangas L; Härkönen P; Väänänen K; Peng Z
Horm Metab Res; 2014 Jan; 46(1):27-35. PubMed ID: 24108389
[TBL] [Abstract][Full Text] [Related]
16. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
17. Excessive L-thyroxine therapy decreases femoral bone mineral densities in the male rat: effect of hypogonadism and calcitonin.
Ongphiphadhanakul B; Alex S; Braverman LE; Baran DT
J Bone Miner Res; 1992 Oct; 7(10):1227-31. PubMed ID: 1456090
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of amlodipine on rat bone tissue after orchidectomy.
Gradosova I; Zivna H; Palicka V; Hubena S; Svejkovska K; Zivny P
Pharmacology; 2012; 89(1-2):37-43. PubMed ID: 22302040
[TBL] [Abstract][Full Text] [Related]
19. Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometric study.
Erben RG; Eberle J; Stahr K; Goldberg M
J Bone Miner Res; 2000 Jun; 15(6):1085-98. PubMed ID: 10841177
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
